European Journal of Cancer
Volume 46, Issue 2 , Pages 284-297 , January 2010

Redefining the role of interferon in the treatment of malignant diseases

  • Sergio Bracarda

      Affiliations

    • Department of Oncology and U.O.C. of Medical Oncology, Ospedale San Donato, Azienda USL-8, 52100 Arezzo, Italy
    • Corresponding Author InformationCorresponding author: Address: Department of Oncology and U.O.C. of Medical Oncology, Ospedale San Donato, AUSL-8, Via Pietro Nenni, 20, 52100 Arezzo, Italy. Tel.: +39 0575 25 5439; fax: +39 0575 25 5435.
    • ,
  • Alexander M.M. Eggermont

      Affiliations

    • Erasmus University MC – Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    • ,
  • Jan Samuelsson

      Affiliations

    • Karolinska Institute, Department of Clinical Science and Education, Department of Internal Medicine, Stockholm South Hospital, 118 83 Stockholm, Sweden

Received 28 July 2009 ,Revised 18 September 2009 ,Accepted 9 October 2009.

References 

  1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–267
  2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32
  3. Billiau A. Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev. 2006;17(5):381–409
  4. Håkansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996;74(5):670–676
  5. Grander D, Einhorn S. Interferon and malignant disease–how does it work and why doesn’t it always?. Acta Oncol. 1998;37(4):331–338
  6. Gerber SA, Pober JS. IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol. 2008;181(2):1052–1062
  7. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95(6):437–448
  8. Raig ET, Jones NB, Varker KA, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res. 2008;28(9):553–562
  9. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282(28):20047–20051
  10. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976;295(10):517–522
  11. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA. 1969;63(1):51–57
  12. Balkwill FR, Oliver RT. Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. Int J Cancer. 1977;20(4):500–505
  13. Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem. 1992;50(1):1–9
  14. Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci USA. 1992;89(1):402–406
  15. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000;5:D479–D487
  16. Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 1999;18(18):2798–2810
  17. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92(10):4562–4566
  18. Yanase N, Kanetaka Y, Mizuguchi J. Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep. 2007;18(4):1031–1038
  19. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6(6):872–879
  20. Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21(8):1251–1262
  21. Thyrell L, Hjortsberg L, Arulampalam V, et al. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem. 2004;279(23):24152–24162
  22. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96(6):2093–2099
  23. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008;112(3):542–550
  24. Finazzi G, Barbui T. Expertise-based management in essential thrombocythemia and polycythemia vera. Cancer J. 2007;13(6):372–376
  25. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90(11):2053–2058
  26. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47(19):5155–5161
  27. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res. 1986;46:1–265
  28. Einhorn S, Strander H. Interferon treatment of human malignancies–a short review. Med Oncol Tumor Pharmacother. 1993;10(1–2):25–29
  29. Friedman RM. Clinical uses of interferons. Br J Clin Pharmacol. 2008;65(2):158–162
  30. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592
  31. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96
  32. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170(6 Pt 1):2163–2172
  33. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel–Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726–4734
  34. Bladder and renal cell carcinomas. In: Fauci AS, Braunwald E, Kasper DL et al., editors. Harrison’s principles of internal medicine. 17th ed. Columbus: McGraw-Hill Professional; 2008.
  35. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;(1):CD001425
  36. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. BJU Int. 2007;99(5 Pt B):1282–1288
  37. Mickisch GH. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol. 2003;43(6):670–679
  38. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–296
  39. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110(11):2468–2477
  40. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985;3(11):1522–1528
  41. Kirkwood JM, Harris JE, Vera R, et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985;45(2):863–871
  42. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987;5(2):286–291
  43. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995;45(5):758–762
  44. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–2867
  45. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353(9146):14–7.
  46. Mickisch GH, Garin A, van PH, de PL, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–970
  47. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659
  48. Dummer R, Hauschild A, Jost L. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl. 2):ii86–ii88
  49. White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2, 505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235(6):879–887
  50. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4(12):748–759
  51. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer. 2004;40(12):1825–1836
  52. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17
  53. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–2458
  54. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776–2783
  55. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189–1196
  56. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358(9285):866–869
  57. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53–61
  58. Grob JJ, Dreno B, de la SP, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905–1910
  59. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195–1201
  60. Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390–402
  61. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–126
  62. National Comprehensive Cancer Network. Melanoma. Available at: <http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf>; 2008.
  63. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20(7):1818–1825
  64. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29(4):241–252
  65. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–1677
  66. Wheatley K, Ives N, Eggermont A, et al. Interferon-alpha as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007;25(18S):478s;[Abstract 8526]
  67. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008;5(1):2–3
  68. Bajetta E. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Nat Clin Pract Oncol. 2008;5(1):4–5
  69. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709–718
  70. Bouwhuis MG, Suciu S, Testori A, et al. Prognostic value of autoantibodies (auto-AB) in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b (PEG-IFN) vs observation. J Natl Cancer Inst. 2009;101:869–877
  71. Bouwhuis MG, Suciu S, Testori A, et al. Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon alpha 2b vs observation. EJC Supplements. 2007;5(6):5LB
  72. Eggermont AM, Suciu S, Testori A, Patel P, Spatz A. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients. J Clin Oncol. 2009;27(15S):462s;[Abstract 9007]
  73. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002;20(7):1826–1831
  74. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148
  75. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459–468
  76. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513–523
  77. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232
  78. Kiladjian JJ, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain JD. Long-term outcome in polycythemia vera (PV): final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi). Blood. 2008;112(11):616;[Abstract 1746a]
  79. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33–45
  80. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110(3):577–583
  81. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89(7):2319–2327
  82. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990–1998
  83. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–3072
  84. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98(1):100–109
  85. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematol-Hematol J. 2005;90(10):1333–1338
  86. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107(3):451–458
  87. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P, Bjorkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006;91(9):1281–1282
  88. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9):2012–2018
  89. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, et al. Pegylated interferon-ALFA-2A (PEG-IFN-{alpha}-2A; PEGASYS) therapy renders high clinical and molecular response rates in patients with essential thrombocythemia (ET) and polycythemia VERA (PV). Blood. 2008;112(11):[Abstract 658]
  90. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol. 1993;66(3):161–162
  91. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86(2):402–404
  92. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101(8):3294–3301
  93. Larsen TS, Moller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on seven patients in sustained complete hematological remission with major molecular responses. Blood. 2008;112(11):615–616[Abstract 1744a]
  94. Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006;107(9):2254–2261
  95. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58(4):808–814
  96. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5(10):2726–2734
  97. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73(1):3–29
  98. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106(7):1431–1442
  99. Jonasch E, Haluska FG. Interferon in oncological practice. review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34–55
  100. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15(7):419–429
  101. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061
  102. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037–2040
  103. Wild PJ, Meyer S, Landthaler M, Hofstaedter F, Bosserhoff AK. A potential predictive marker for response to interferon in malignant melanoma. J Dtsch Dermatol Ges. 2007;5(6):456–459
  104. Ito N, Eto M, Nakamura E, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25(19):2785–2791
  105. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33(8):665–680
  106. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028–1043
  107. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342
  108. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676
  109. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550
  110. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111
  111. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–5428
  112. Kondagunta GV, Hudes G, Figlin R, et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study. J Clin Oncol. 2007;25(18S):260s;[Abstract 5101]
  113. Ryan CW, Goldman BH, Lara PN, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–3301
  114. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25(22):3288–3295
  115. Bracarda S, Porta C, Boni C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. Presented at 2008 Genitourinary Cancers Symposium 14–16 February 2008 [Abstract 357].
  116. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281
  117. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;27(15S):239s;[Abstract 5020]
  118. Rini BI, Halabi S, Rosenberg J, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol. 2008;27(18S):798s;[Abstract LBA5019]
  119. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19(8):1470–1476
  120. Tannir N, Zurita AJ, Heymach JV, et al. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: clinical results and biomarker analysis. J Clin Oncol. 2008;26(15S):272s;[Abstract 5093]
  121. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14(8):2367–2376

PII: S0959-8049(09)00760-6

doi: 10.1016/j.ejca.2009.10.013

European Journal of Cancer
Volume 46, Issue 2 , Pages 284-297 , January 2010

Article Tools

* Image Usage & Resolution